Cetuximab concomitant with XXXX and radiotherapy in advanced @entity957 of upper aerodigestive tract: a pilot study.

@entity1 @entity135 @entity137 @entity390 @entity2905 @entity957 @entity33 @entity1398 @entity136
PURPOSE: To explore the response and @entity137 of advanced non-metastatic @entity957 of upper aerodigestive tract (SCC-UADT) to a combination of cetuximab concomitant with @entity136 and radiotherapy. METHODS: We managed @entity1 with concomitant treatment of cetuximab (400 mg/m(2) as uploading dose, then 250 mg/m(2), IV) concomitant with @entity136 (50 mg/m(2)) weekly for seven courses, and radiotherapy in classical fractionation until completion of 70 Gy. Primary endpoints were complete response (CR) to treatment and @entity137 . We evaluated @entity1 for @entity137 on a weekly basis; evaluation of response included physical examination, endoscopy, computed tomography (CT) scan and biopsy when indicated, and was performed 6 weeks after completion of radiotherapy. Additional evaluations were done every 3 months to document disease status. Between November 2004 and November 2005, 20 @entity1 were included. RESULTS: CR was 82.4%, overall response was 100%. @entity135 reached CR in 61.5% and partial in 38.5% of @entity1 . The main @entity137 were @entity390 , @entity2905 , @entity1398 and @entity33 . Grade 3 and 4 side effects were presented in 70.6% of @entity1 , but @entity33 , and @entity2905 without clinical repercussions, occurred in 88.2% of @entity1 . Gastrostomy was required in 11.8% of @entity1 to maintain nutrition. Radioepithelitis developed in 76.5%, but only three of these (23.1%) were grade III. Median overall survival was 53 months (range 6-55 months) and median progression-free survival has not yet been reached at the time of evaluation. CONCLUSIONS: Although @entity137 is important, this approach has interesting activity and deserves further investigation.
